专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20100196423A1 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases 有权
标题翻译：可溶性糖胺聚糖酶和制备和使用可溶性糖胺聚糖酶的方法
公开(公告)号：US20100196423A1
公开(公告)日：2010-08-05
申请号：US12660893
申请日：2010-03-04
申请人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
发明人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
IPC分类号： A61K39/08 , A61K35/12 , A61K38/46
CPC分类号： A61K38/47 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C12N9/2408 , C12Y302/01035 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
摘要翻译：本发明涉及新型可溶性中性活性透明质酸酶糖蛋白（sHASEGPs）的发现，其制备方法及其用于促进其它分子的施用或减轻糖胺聚糖相关病理学的用途。描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。包括改进的氨基末端前导肽，其增强sHASEGP的分泌。本发明还包含重组sHASEGP的唾液酸化和聚乙二醇化形式，以增强天然存在的屠宰酶的稳定性和血清药代动力学。进一步描述了衍生自真核细胞的基本上纯化的重组sHASEGP糖蛋白的合适制剂，其产生其最佳活性所需的适当糖基化。

22. 发明申请

US20100015698A1 Human Chondroitinase Glycoprotein (CHASEGP), Process for Preparing the Same, and Pharmaceutical Compositions Comprising Thereof 有权
标题翻译：人类软骨素糖蛋白（CHASEGP），其制备方法以及包含其的药物组合物
公开(公告)号：US20100015698A1
公开(公告)日：2010-01-21
申请号：US12475221
申请日：2009-05-29
申请人： Gregory I. Frost , Anirban Kundu , Louis H. Bookbinder
发明人： Gregory I. Frost , Anirban Kundu , Louis H. Bookbinder
IPC分类号： C12N9/10 , C07H21/04 , C12N15/63
CPC分类号： C12N9/88 , A61K38/47 , C12Y402/02004
摘要： The invention relates to the discovery of novel Chondroitinase Glycoproteins (CHASEGPs), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value.
摘要翻译：本发明涉及在去除硫酸软骨素可能具有治疗益处的条件下发现新型软骨素酶糖蛋白（CHASEGP），制造方法和潜在用途。软骨素酶糖蛋白需要CHASEGP多肽的大部分催化结构域和天冬酰胺连接的糖基化以获得最佳的软骨素酶活性。本发明还包括CHASEGP的羧基末端缺失变体，其导致蛋白质的分泌型变体以促进重组CHASEGP的制备。进一步描述了衍生自真核细胞的基本上纯化的重组CHASEGP糖蛋白的合适制剂，其产生其最佳活性所需的适当糖基化。 CHASEGP可用于在其去除具有治疗价值的临床条件下降解糖胺聚糖和硫酸软骨素蛋白聚糖。

23. 发明申请

US20050260186A1 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases 有权
标题翻译：可溶性糖胺聚糖酶和制备和使用可溶性糖胺聚糖酶的方法
公开(公告)号：US20050260186A1
公开(公告)日：2005-11-24
申请号：US11065716
申请日：2005-02-23
申请人： Louis Bookbinder , Anirban Kundu , Gregory Frost , Michael Haller , Gilbert Keller , Tyler Dylan
发明人： Louis Bookbinder , Anirban Kundu , Gregory Frost , Michael Haller , Gilbert Keller , Tyler Dylan
IPC分类号： A01K67/027 , A61K38/17 , A61K38/47 , C07H21/04 , C12N9/24 , C12P21/06
CPC分类号： A61K38/47 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C12N9/2408 , C12Y302/01035 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
摘要翻译：本发明涉及新型可溶性中性活性透明质酸酶糖蛋白（sHASEGPs）的发现，其制备方法及其用于促进其它分子的施用或减轻糖胺聚糖相关病理学的用途。描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。包括改进的氨基末端前导肽，其增强sHASEGP的分泌。本发明还包含重组sHASEGP的唾液酸化和聚乙二醇化形式，以增强天然存在的屠宰酶的稳定性和血清药代动力学。进一步描述了衍生自真核细胞的基本上纯化的重组sHASEGP糖蛋白的合适制剂，其产生其最佳活性所需的适当糖基化。

24. 发明授权

US09677062B2 Hyaluronidase and factor VIII compositions 有权
公开(公告)号：US09677062B2
公开(公告)日：2017-06-13
申请号：US13374500
申请日：2011-12-28
申请人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
发明人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
IPC分类号： C12N9/24 , C12N9/26 , A61K9/00 , A61K38/47 , A61K47/48
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

25. 发明授权

US09677061B2 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof 有权
公开(公告)号：US09677061B2
公开(公告)日：2017-06-13
申请号：US12928890
申请日：2010-12-21
申请人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
发明人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
IPC分类号： C12N9/24 , C12N9/26 , A61K9/00 , A61K38/47 , A61K47/48
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

26. 发明申请

US20140199282A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof 有权
公开(公告)号：US20140199282A1
公开(公告)日：2014-07-17
申请号：US13999454
申请日：2014-02-26
申请人： Louis Bookbinder , Anirban Kundu , Gregory I. Frost
发明人： Louis Bookbinder , Anirban Kundu , Gregory I. Frost
IPC分类号： C12N9/26 , A61K47/48 , A61K38/47 , A61K9/00
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

27. 发明授权

US08772246B2 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof 有权
标题翻译：可溶性透明质酸酶糖蛋白（sHASEGP），其制备方法，用途及其组合物
公开(公告)号：US08772246B2
公开(公告)日：2014-07-08
申请号：US13694005
申请日：2012-10-18
申请人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
发明人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
IPC分类号： A61K38/14 , A61K38/17 , C12N9/26
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
摘要翻译：提供可溶性中性活性透明质酸酶糖蛋白（sHASEGP），其制备方法及其用于促进其它分子的给药或减轻糖胺聚糖相关病理学的用途。描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。包括改进的氨基末端前导肽，其增强sHASEGP的分泌。还提供了sHASEGP的唾液酸化和聚乙二醇化形式。还提供了通过施用sHASEGP的治疗方法及其修饰形式。

28. 发明授权

US08765685B2 Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP) 有权
标题翻译：通过施用可溶性透明质酸糖蛋白（sHASEGP）治疗水肿的方法
公开(公告)号：US08765685B2
公开(公告)日：2014-07-01
申请号：US13506783
申请日：2012-05-16
申请人： Louis Bookbinder , Anirban Kundu , Gregory I. Frost
发明人： Louis Bookbinder , Anirban Kundu , Gregory I. Frost
IPC分类号： A61K38/14 , A61K38/17 , C12N9/26
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
摘要翻译：提供可溶性中性活性透明质酸酶糖蛋白（sHASEGP），其制备方法及其用于促进其它分子的给药或减轻糖胺聚糖相关病理学的用途。描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。包括改进的氨基末端前导肽，其增强sHASEGP的分泌。还提供了sHASEGP的唾液酸化和聚乙二醇化形式。还提供了通过施用sHASEGP的治疗方法及其修饰形式。

29. 发明授权

US08580252B2 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases 有权
公开(公告)号：US08580252B2
公开(公告)日：2013-11-12
申请号：US13507540
申请日：2012-07-06
申请人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
发明人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
IPC分类号： A61K38/46 , A61P35/00
CPC分类号： A61K38/47 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C12N9/2408 , C12Y302/01035 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

30. 发明授权

US08257699B2 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases 有权
公开(公告)号：US08257699B2
公开(公告)日：2012-09-04
申请号：US13374248
申请日：2011-12-15
申请人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
发明人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost
IPC分类号： A61K38/46 , A61K38/55
CPC分类号： A61K38/47 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C12N9/2408 , C12Y302/01035 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式